Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint

(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

31 Jan 2021

Study finds protective genetic associations with mild COVID-19

Using self-reported survey data, researchers have defined eight phenotypes associated with COVID-19 outcomes. Analysis of the data revealed possible protective genetic associations.

29 Jan 2021

Variants emerging during COVID-19 pandemic resist antibody neutralization

Researchers in the U.S. have warned that recently emerged variants of SARS-CoV-2 have become worryingly resistant to monoclonal antibody therapies, plasma from convalescent patients and sera from vaccinated individuals.

28 Jan 2021

Researchers engineer antibody that broadly neutralizes a range of clade 1 sarbecoviruses

Researchers have engineered an antibody that neutralizes SARS-CoV-2 with a potency that "rivals" current lead SARS-CoV-2 clinical neutralizing antibodies, and that also broadly neutralizes a range of clade 1 sarbecoviruses.

26 Jan 2021

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

With the emergence of COVID-19 (coronavirus disease 2019), researchers have been closely investigating the complex interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the human immune system, and COVID-19 disease severity.

25 Jan 2021

Combining anti-tumor antibodies with standard-of-care improves therapeutic outcomes in cancer

The cover for issue 2 of Oncotarget features Figure 4, "Combination therapy TA99/ICB reduced the lung tumor burden in the B16 model of metastases," published in "Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma" by Pérez-Lorenzo, et al. which reported that here, the authors showed that removing immune suppression and enhancing stimulatory signals increased the anti-tumor activity of unmodified TA99 antibodies with a significant reduction of growth of solid tumors and lung metastases in mouse models of melanoma.

25 Jan 2021

New data on impact of spike mutations and B117 UK variant on neutralization by mAbs and sera

A recent paper by British and Dutch scientists, currently available on the bioRxiv* preprint server, shows that the neutralizing activity of monoclonal antibodies can be dramatically reduced by mutations of the SARS-CoV-2 spike glycoprotein – unlike polyclonal antibodies generated after natural infection that remain active regardless of any introduced amino acid changes.

21 Jan 2021

Dynamic, customized treatment approaches for gastroesophageal cancers may improve survival rates

A phase 2 clinical trial providing personalized treatments based on the genetic profile of metastatic tumors in gastroesophageal cancers has found that using customized treatment approaches, and adapting them over time as tumors become resistant, led to higher rates of survival compared to historical controls.

21 Jan 2021

Patients fend for themselves to access highly touted covid antibody treatments

By the time he tested positive for covid-19 on Jan. 12, Gary Herritz was feeling pretty sick. He suspects he was infected a week earlier, during a medical appointment in which he saw health workers who were wearing masks beneath their noses or who had removed them entirely.

20 Jan 2021

Researchers develop new method for charting SARS-CoV-2 spike protein glycosylation

Researchers develop a novel, simple and affordable method for N-glycan fingerprinting based on enzymatic fluorescent glycan labeling and electrophoresis. This new method may help us understand important changes in glycosylation in the SARS-CoV-2 spike protein – something which could inform future therapeutic research.

20 Jan 2021

Immune systems of COVID-19 patients may rely on antibodies from earlier coronaviruses

The results of a study led by Northern Arizona University and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest the immune systems of people infected with COVID-19 may rely on antibodies created during infections from earlier coronaviruses to help fight the disease.

20 Jan 2021

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

A new study suggests that modified natural killer cells, which express a chimeric antigen receptor using S309 antibody, can bind to and inactivate SARS-CoV-2 spike protein in vitro.

18 Jan 2021

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

An encouraging new study describes a promising new therapeutic antibody that shows potent neutralizing activity against SARS-CoV-2, the causative agent of COVID-19.

15 Jan 2021

Discovery of SARS-CoV-2 neutralizing antibodies from a naïve human Ab library

Now, a new preprint research paper published on the bioRxiv server shows how closely the antibodies formed in exposed humans resemble the germline antibody molecules. This could lead to the development of novel therapeutics to counter the pandemic.

12 Jan 2021

Vimentin could be a major co-factor that aids SARS-CoV-2 infection

A recent study has found that extracellular vimentin can bind to SARS-CoV-2 spike protein in vitro, and antibodies against vimentin can decrease virus infectivity by up to 80%. This suggests vimentin could aid the virus’s binding to host cells and help in infection.

11 Jan 2021

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Proteogenomic analysis may offer new insight into matching cancer patients with an effective therapy for their particular cancer.

7 Jan 2021

Researchers provide comprehensive molecular characterization of head and neck cancers

In what is believed to be the most comprehensive molecular characterization to date of the most common type of head and neck cancer, researchers from the Johns Hopkins departments of pathology and oncology, the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine, and 18 other centers around the U.S. and Poland have clarified the contribution of key cancer-associated genes, proteins and signaling pathways in these cancers, while proposing possible new treatment avenues.

7 Jan 2021

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

A large clinical trial, known as the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-2), is set to take place, which aims to test monoclonal antibody efficacy and safety in people who have mild or moderate COVID-19.

6 Jan 2021

UMSOM researchers find greatest risk factors for death in hospitalized COVID-19 patients

Hospitalized COVID-19 patients have a greater risk of dying if they are men or if they are obese or have complications from diabetes or hypertension, according to a new study conducted by University of Maryland School of Medicine researchers.

18 Dec 2020

Monoclonal Antibody News and Research

Further Reading

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint

Study finds protective genetic associations with mild COVID-19

Variants emerging during COVID-19 pandemic resist antibody neutralization

Researchers engineer antibody that broadly neutralizes a range of clade 1 sarbecoviruses

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

Combining anti-tumor antibodies with standard-of-care improves therapeutic outcomes in cancer

New data on impact of spike mutations and B117 UK variant on neutralization by mAbs and sera

Dynamic, customized treatment approaches for gastroesophageal cancers may improve survival rates

Patients fend for themselves to access highly touted covid antibody treatments

Researchers develop new method for charting SARS-CoV-2 spike protein glycosylation

Immune systems of COVID-19 patients may rely on antibodies from earlier coronaviruses

Modified natural killer cells show neutralizing and multivalent potential against SARS-CoV-2 in vitro

Study reports promising new monoclonal antibody against SARS-CoV-2’s spike protein

Discovery of SARS-CoV-2 neutralizing antibodies from a naïve human Ab library

Vimentin could be a major co-factor that aids SARS-CoV-2 infection

Proteogenomics can help determine effective treatment for head and neck squamous cell carcinoma

Researchers provide comprehensive molecular characterization of head and neck cancers

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

UMSOM researchers find greatest risk factors for death in hospitalized COVID-19 patients

Antibodies eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®